The aim of this study was to report the success of a clindamycin graded challenge. The patient was a 39-year-old human immunodeficiency virus-infected male with toxoplasmic encephalitis (TE) with a history of trimethoprim/sulfamethoxazole (TMP/SMX) and clindamycin allergy. He developed a reaction during TMP/SMX desensitization. Following the reaction, a graded challenge with clindamycin was performed in this study, and he became tolerant to clindamycin. No adverse drug reactions developed during the graded challenge. He successfully continued suppressive therapy with no further reactions or recurrences.

Keywords: Clindamycin; Graded challenge; Toxoplasmic encephalitis; AIDS patient

INTRODUCTION

Toxoplasmic encephalitis (TE) is found in 23.2% of patients with acquired immune deficiency syndrome (AIDS) in Thailand [1]. Recently, there has been a scarcity of TE treatment regimen. Therefore, a graded challenge is one method of safely using suspected medications in patients with a history of minor adverse drug reactions (ADRs) and multiple drug allergies needing medications to treat TE.

A graded challenge is defined as an administration of progressively increasing doses of a medication until a therapeutic dose is reached. The objective of a graded challenge is to verify or exclude the reaction in patients who are unlikely to be allergic to a specific medication. When the reaction is non-immunoglobulin E (IgE) mediated, graded challenges are a recommendable strategy to reintroduce medication. The patient who tolerates a graded challenge without allergic reactions is considered as nonallergy [2, 3]. Herein, we describe the case of an AIDS patient with a history of trimethoprim/sulfamethoxazole (TMP/SMX) and clindamycin allergy who was reintroduced to clindamycin by a graded challenge strategy to treat TE.
CASE REPORT

This is a case report of a 39-year-old male who was diagnosed with AIDS-associated TE in March 2016. At the time of human immunodeficiency virus (HIV) and TE Diagnosis, the patient had an absolute CD4 T lymphocyte cell count of 39.5 cells/μL. He had not been started on any antiretroviral agents because the physicians planned to initiate them after the completion of TE treatment. Initially, the patient received TMP/SMX for TE treatment as an inpatient. One week after starting TMP/SMX, he developed a drug reaction with eosinophilia and systemic symptoms (DRESS) with blood eosinophil 7%, aspartate transaminase (AST) 452 U/L and alanine transaminase (ALT) 248 U/L, so the antibiotic was switched from TMP/SMX to clindamycin. His allergic reaction was treated with chlorpheniramine for 10 days. DRESS slowly resolved after TMP/SMX was discontinued. The patient was discharged with clindamycin monotherapy with a plan to start pyrimethamine and leucovorin as an outpatient. Eleven days after clindamycin was started (approximately 1-2 days after chlorpheniramine was discontinued), he developed maculopapular rash on the face, trunk, extremities, and abdomen. There is no relationship between the potential causes of this reaction and the course of other medications. The causal relationship between this reaction and clindamycin was evaluated by using an ADR probability scale, Naranjo Algorithm, and then categorized as “probable.” All reactions disappeared within a week after discontinuation of clindamycin. Eventually, with the patient’s consent, we decided to do TMP/SMX desensitization. Unfortunately, he suffered from conjunctivitis and maculopapular rash during TMP/SMX desensitization.

This patient had a history of minor ADRs to clindamycin and needed medications to treat TE; therefore, we decided to do a graded challenge of clindamycin and planned to use it in combination with pyrimethamine and leucovorin. The risks and benefits of a clindamycin graded challenge were explained to the patient and informed consent was obtained. A clindamycin graded challenge was initiated by using the protocol described in a case report [4]. The 7-day oral clindamycin graded challenge protocol used in our case report is shown in Table 1. The starting dose of clindamycin was 20 mg every 8 hours on day 1. The drug dose was then progressively increased until reaching a full dose of 600 mg 4 times per day within 7 days. Our patient did not develop any allergic reactions during the 7 days graded challenge. After completion of the graded challenge, the patient continued to take therapeutic doses of clindamycin with pyrimethamine, azithromycin and leucovorin for 12 weeks. Eventually, the TE was resolved.

The risks and benefits of a clindamycin graded challenge were explained to the patient and informed consent was obtained. The Institution Review Board of institute approved the report (REC.59-225-19-2).

| Day | Preparation | Dose (mg) | Administration |
|-----|-------------|-----------|----------------|
| 1   | Clindamycin capsule 150 mg dissolved in 50 mL water | 20 | 6.7 mL TID |
| 2   | 40 | 13.3 mL TID |
| 3   | 80 | 26.7 mL TID |
| 4   | Clindamycin capsule 150 mg | 150 | 150 mg, 1 capsule TID |
| 5   | Clindamycin capsule 300 mg | 300 | 300 mg, 1 capsule TID |
| 6   | Clindamycin capsule 300 mg | 600 | 300 mg, 2 capsule TID |
| 7   | Clindamycin capsule 300 mg | 600 | 300 mg, 2 capsule QID |

TID, 3 times per day; QID, 4 times per day.

https://doi.org/10.5415/apallergy.2022.12.e36
DISCUSSION

The patient developed DRESS, a severe cutaneous adverse reaction, during TMP/SMX desensitization. Therefore, TMP/SMX and other sulfonamides antibiotic were contraindicated in this patient. The report of SMX and sulfadiazine cross allergy was 31.8% [5]. At this case report time period, the preferred alternative regimens are clindamycin or azithromycin plus pyrimethamine plus leucovorin. Based on the Thailand National Guidelines on HIV/AIDS Treatment and Prevention 2014 [6, 7], the regimen containing clindamycin is strongly recommended with level I quality of evidence (“one or more randomized trials with clinical outcomes”) while the regimen containing has an optional recommendation with level II quality of evidence (“one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes”). There was no statistically significant difference in efficacy between the combination of pyrimethamine plus clindamycin and pyrimethamine plus sulfadiazine regimens. There was a complete or partial response in 68% and 76%, respectively [8]. The complete or partial response of azithromycin in combination with pyrimethamine for treatment of acute TE in patients with AIDS for 4 weeks was achieved in 35.7% of patients [9].

Our patient had a history of non-serious allergic reactions to clindamycin. The data mentioned above shows that this regimen is effective and has been recommended by peer-review guidelines to treat TE. Therefore, we chose to do a clindamycin graded challenge, expecting greater benefits than risks. Generally, the graded challenge has been recommended in non-IgE mediated reactions. Our patient developed a maculopapular rash 11 days after starting clindamycin, suggests that non-IgE mediated hypersensitivity reactions in nature, though the exact mechanism still remains unclear. The incidence of drug hypersensitivity reactions increases in patients with opportunistic infections who have very low CD4 T lymphocyte cell count [10, 11]. A low incidence (0.4% – 3%) in clindamycin hypersensitivity has been reported [12]. The clinical presentation of clindamycin hypersensitivity reported in literature includes angioedema, generalized maculopapular pruritic reaction, DRESS, Stevens-Johnson syndrome and toxic epidermal necrolysis [12, 13]. Moreover, it is possible that the hypersensitivity state remained for 4–6 weeks after the first episode of TMP/SMX allergy because of the increasing function of the immune system [10, 11]. Flare up reaction was reported in 25% of patients with DRESS, skin eruptions were the most prevalent presentation of the recurrences, followed by eosinophilia in about half of the cases and internal organ damage in 13% of the cases [14]. Our patient developed maculopapular rash on the face, trunk, extremities, and abdomen, and blood eosinophil 10%, normal AST and ALT. Therefore, a self-reported history of maculopapular rash from clindamycin might not, actually, be a clindamycin allergy.

Currently, many drug graded challenge protocols have been reported as successful in multiple research articles. The drugs that the graded challenge protocols have published worldwide include acyclovir, fluconazole, and TMP/SMX [15-17].

There are a few reports of clindamycin graded challenge protocols. Marcos et al. [4] reported a patient case with HIV infections who developed a cutaneous eruption after 12 days of TE treatment with clindamycin. The authors progressively increased the dose of clindamycin to reach the full dose within 7 days [4]. The recent study showed the success of rapid (240 minute) oral clindamycin desensitization in a pediatric patient who experienced an anaphylactoid reaction from clindamycin. However, the patient tolerated clindamycin...
with 3 premedication regimens (cetirizine 10 mg every 8 hours, montelukast 5 mg daily and ranitidine 60 mg every 12 hours the whole time of clindamycin using) [18]. This protocol might not be practical since the patient with HIV infection needed to take high amounts of medication for a long duration of time.

REFERENCES

1. Sukthana Y, Chintana T, Lekkla A. Toxoplasma gondii antibody in HIV-infected persons. J Med Assoc Thai 2000;83:681-4.
   PUBMED

2. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010;105:259-73.
   PUBMED | CROSSREF

3. Khan DA, Solensky R. Drug allergy. J Allergy Clin Immunol 2010;125(2 Suppl 2):S126-37.
   PUBMED | CROSSREF

4. Marcos C, Sopeña B, Luna I, González R, de la Fuente J, Martínez-Vázquez C. Clindamycin desensitization in an AIDS patient. AIDS 1995;9:1201-2.
   PUBMED | CROSSREF

5. Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. Contact Dermat 2004;51:57-62.
   PUBMED | CROSSREF

6. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America 2019 [Internet]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.

7. Thai AIDS Society. Thailand national guidelines on HIV/AIDS treatment and prevention 2017 [Internet]. Bureau of AIDS, TB and STIs Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand; 2017. Available from: http://www.ilo.org/dyn/natlex/docs/ELECTRONIC/112761/141007/F-1494608944/THA112761.pdf.

8. Katlama C, De Wit S, O’Doherty E, Van Glabeke M, Clumeck N. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996;22:268-75.
   PUBMED | CROSSREF

9. Saba J, Morlat P, Raffi F, Hazebroucq V, Leboy V, Leport C, Vildé JL. Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. Eur J Clin Microbiol Infect Dis 1993;12:853-6.
   PUBMED | CROSSREF

10. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328:1670-4.
    PUBMED | CROSSREF

11. Todd G. Adverse cutaneous drug eruptions and HIV: a clinician's global perspective. Dermatol Clin 2006;24:459-72, vi.
    PUBMED | CROSSREF

12. Mazur N, Greenberger PA, Regalado J. Clindamycin hypersensitivity appears to be rare. Ann Allergy Asthma Immunol 1999;82:443-5.
    PUBMED | CROSSREF

13. Nakamura Y, Watamatsu K, Muto M. Drug-induced hypersensitivity syndrome induced by clindamycin. Acta Derm Venereol 2013;93:83-4.
    PUBMED | CROSSREF

14. Cho YT, Yang CW, Chu CY. Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system. Int J Mol Sci 2017;18:1243.
    PUBMED | CROSSREF

15. Demoly P, Messaad D, Reyes J, Faucherre V, Bousquet J. Trimethoprim-sulfamethoxazole-graded
15. Chiesa F, D’Arpa V, Bruni B, et al. Clindamycin graded challenge strategy in HIV-infected patients: long-term follow-up regarding efficacy and safety. J Allergy Clin Immunol 2000;105:588-9.

PUBMED | CROSSREF

16. Kawsar M, Parkin JM, Forster G. Graded challenge in an aciclovir allergic patient. Sex Transm Infect 2001;77:204-5.

PUBMED | CROSSREF

17. Rankin BT, Jariwala S. Graded challenge protocol for fluconazole hypersensitivity in a patient with cryptococcal pneumonitis. Ann Allergy Asthma Immunol 2012;108:466.

PUBMED | CROSSREF

18. Esty B, Minnicozzi S, Chu EC, Broyles AD, Yee CSK. Successful rapid oral clindamycin desensitization in a pediatric patient. J Allergy Clin Immunol Pract 2018;6:2141-2.

PUBMED | CROSSREF